Drug Profile
Research programme: anti-neuropilin monoclonal antibodies - Eli Lilly and Company
Alternative Names: anti-NRP-antibodies; Neuropilin MAbLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator ImClone Systems
- Developer Eli Lilly and Company
- Class Monoclonal antibodies
- Mechanism of Action Vascular endothelial growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Solid-tumours in USA (Parenteral, Injection)
- 26 Jul 2006 Preclinical trials in Solid tumours in USA (Parenteral)